Hyaluronic Acid Turbidimetric Assay Compared to Standard Method
|
By LabMedica International staff writers Posted on 13 Jan 2016 |
|
Image: The Hitachi 917 Automatic Disk-Chemistry Analyzer (Photo courtesy of Roche Diagnostics).
Circulating hyaluronic acid (HA) in human adults is primarily produced in the peripheral soft connective tissue and transported to the systemic circulation via lymph drainage and the majority of HA is removed from circulation by hepatic elimination.
HA is essentially non-immunogenic, which has excluded direct immunochemical methods of measurement. To accommodate this, several advanced methods of measurements have been used including enzymatic degradation; hyaluronic-binding protein (HABP) linked enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography.
Scientists at the Nordsjaellands Hospital, University of Copenhagen, (Denmark) and their colleagues measured HA concentrations in 39 samples of serum from 39 randomly selected intensive care unit (ICU) patients. The HA was measured by a particle-enhanced turbidimetric immunoassay (PETIA) and enzyme-linked immunosorbent assay (ELISA) in a 40-sample dilution series and the 39 ICU patients.
The HA was measured with the PETIA (Corgenix; Broomfield, CO, USA) in ICU samples on the Hitachi 917 (Roche Diagnostics, GmbH; Mannheim, Germany) and in the dilution series on Modular P (Roche Diagnostics GmbH) analyzers (test assay), and by Corgenix HA ELISA using double determination (reference method).
The scientists found that in the ICU patients, the median HA concentration was 159.0 ng/mL (interquartile range (IQR) 117.5–362.5 ng/mL) with ELISA and 157.5 ng/ml (IQR 92.5–359.6 ng/mL) with PETIA. The mean difference was 12.88 ng/mL which was statistically significant and the 95% limits of agreement were −91.17 to 116.9 ng/mL. In the dilution series, the mean difference was −59.26 ng/mL (95% CI, −74.68 to 43.84 ng/mL, and the 95% limits of agreement were 35.23 to −153.8 ng/mL.
The authors concluded that there was random variation between the PETIA and ELISA test that could affect performance in a clinical context. The new clinical biochemistry assay for HA determination will allow for large studies of the clinical utility of HA. The study was published online on December 14, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Nordsjaellands Hospital
Corgenix
Roche Diagnostics GmbH
HA is essentially non-immunogenic, which has excluded direct immunochemical methods of measurement. To accommodate this, several advanced methods of measurements have been used including enzymatic degradation; hyaluronic-binding protein (HABP) linked enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography.
Scientists at the Nordsjaellands Hospital, University of Copenhagen, (Denmark) and their colleagues measured HA concentrations in 39 samples of serum from 39 randomly selected intensive care unit (ICU) patients. The HA was measured by a particle-enhanced turbidimetric immunoassay (PETIA) and enzyme-linked immunosorbent assay (ELISA) in a 40-sample dilution series and the 39 ICU patients.
The HA was measured with the PETIA (Corgenix; Broomfield, CO, USA) in ICU samples on the Hitachi 917 (Roche Diagnostics, GmbH; Mannheim, Germany) and in the dilution series on Modular P (Roche Diagnostics GmbH) analyzers (test assay), and by Corgenix HA ELISA using double determination (reference method).
The scientists found that in the ICU patients, the median HA concentration was 159.0 ng/mL (interquartile range (IQR) 117.5–362.5 ng/mL) with ELISA and 157.5 ng/ml (IQR 92.5–359.6 ng/mL) with PETIA. The mean difference was 12.88 ng/mL which was statistically significant and the 95% limits of agreement were −91.17 to 116.9 ng/mL. In the dilution series, the mean difference was −59.26 ng/mL (95% CI, −74.68 to 43.84 ng/mL, and the 95% limits of agreement were 35.23 to −153.8 ng/mL.
The authors concluded that there was random variation between the PETIA and ELISA test that could affect performance in a clinical context. The new clinical biochemistry assay for HA determination will allow for large studies of the clinical utility of HA. The study was published online on December 14, 2015, in the Journal of Clinical Laboratory Analysis.
Related Links:
Nordsjaellands Hospital
Corgenix
Roche Diagnostics GmbH
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
All-in-One Molecular System
AIO M160
New
Automated Immunoassay Analyzer
SuperFlex™
Latest Immunology News
- Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
- Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
- Prototype Point-of-Care Test Aims to Improve Neonatal Sepsis Diagnosis
- Single-Tier Lyme Disease Test Shows High Sensitivity in Early Infection
- New Web-Based Platform Helps Autoimmune Laboratories Manage Testing Complexity
- Routine Newborn Blood Spots Can Measure GBS Antibody Levels
- New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
- Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
- HIV Monitoring Strategy Uses Drug Levels to Guide Resistance Testing
- Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent
- Blood Biomarker May Predict Colitis Risk in Checkpoint Inhibitor Therapy
- Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
- New Cellular Map May Help Predict Crohn’s Disease Course in Children
- Temporal Immune Profiling Reveals How Sepsis States Change Over Time
- Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
- Gut “Memory” May Explain Why IBD Flares Return
Channels
Molecular Diagnostics
view channel
Study Shows How Genome Reference Bias Can Mislead Preventive Testing
Whole-genome sequencing is expected to play a growing role in preventive and predictive medicine, but accurate interpretation remains a major diagnostic challenge. The approach requires comparing billions... Read more
Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer
For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood-Based Immune Aging Map Could Help Spot Disease Risk Earlier
Chronological age does not always reflect immune health or future disease risk. Two adults of the same age can have immune systems that age very differently, with some remaining resilient while others... Read more
Blood-Based Immune Signal Could Reveal Lung Cancer Risk Before Tumors Develop
Lung cancer remains difficult to detect before symptoms appear, when advanced disease is harder to treat. In the U.K., about 32,800 people die from lung cancer each year, and only 11.1% of those diagnosed... Read more
Microbiology
view channel
Oral and Lung Microbiome Changes Linked to Severe Long Covid Symptoms
Long Covid can involve persistent respiratory, cognitive, and gastrointestinal symptoms after acute infection, creating a difficult diagnostic and management challenge. Because COVID-19 initially affects... Read more
Study Finds Distinct Malaria Parasites Linked to Sickle Cell Trait Protection
Malaria remains one of the world’s deadliest infectious diseases and has affected humans throughout recorded history. In regions where malaria is common, human genetics have been shaped by the sickle cell... Read more
Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis
Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more
Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification
Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read morePathology
view channel
AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
Ewing sarcoma is a rare malignant tumor that mainly affects children, adolescents, and young adults. It usually arises in bone but can also develop in soft tissue, where its microscopic appearance may... Read more
Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Glioma brain tumors are highly infiltrative and can extend into nearby healthy brain tissue, making tumor margins difficult to define during surgery. Residual tumor cells may contribute to recurrence and... Read more
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
Technology
view channel
Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read more
Industry
view channel
Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation
Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
European Approval Expands Liquid Biopsy Use in Advanced Breast Cancer Testing
Estrogen receptor-positive (ER+), HER2-negative advanced breast cancer may require molecular testing to guide treatment selection, with blood-based assays offering a way to identify tumor mutations that... Read more
